tyloxapol has been researched along with Arteriosclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borensztajn, J; Davidson, NO; Fu, T; Mukhopadhyay, D | 1 |
| Inoue, Y; Kurogi, Y; Nagao, K; Nakamura, S; Tsuda, Y; Tsutsumi, K; Yoshitsugu, H | 1 |
2 other study(ies) available for tyloxapol and Arteriosclerosis
| Article | Year |
|---|---|
The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions.
Topics: Animals; Aorta; Apolipoproteins B; Arteriosclerosis; Blotting, Western; Cholesterol; Clofibric Acid; Cytoplasm; Female; Fibric Acids; Intestinal Mucosa; Lipid Metabolism; Lipoproteins; Lipoproteins, LDL; Liver; Mice; Mice, Inbred C57BL; Mice, Transgenic; Peroxisome Proliferators; Polyethylene Glycols; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; RNA; RNA Editing; RNA, Messenger; Time Factors; Transcription Factors; Triglycerides | 2004 |
Synthesis and hypolipidemic activities of novel 2-[4-[diethoxyphosphoryl)methyl]phenyl]quinazolines and 4(3H)-quinazolinones.
Topics: Animals; Arteriosclerosis; Benzamides; Biological Availability; Cholesterol; Chromatography, High Pressure Liquid; Hyperlipidemias; Hypolipidemic Agents; Magnetic Resonance Spectroscopy; Molecular Structure; Organophosphorus Compounds; Polyethylene Glycols; Quinazolines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Triglycerides | 1996 |